Datamonitor Healthcare: data analysis and insight, Pink Shee...
Pharma Intelligence Podcasts
Listen to the Pharma Intelligence podcasts on Spotify, Apple Podcasts, Soundcloud and Alexa
PD-1/PD-L1 Inhibitors: The First Wave of Immuno-Oncology is a comprehensive look at the immuno-oncology landscape, and includes:
· An overview of the current immuno-oncology market
· Ongoing developments in the PD-1/PD-L1 therapy space
· Challenges with PD-1/PD-L1 inhibitor development and treatment
· An examination of:
o Non-small cell lung cancer (NSCLC)
o Bladder cancer
· A look at the future of immuno-oncology
Watch webinar recording here
Datamonitor Healthcare: data analysis and insight, Pink Shee...
Listen to the Pharma Intelligence podcasts on Spotify, Apple Podcasts, Soundcloud and Alexa
Topics Coronavirus $name $name Clinical Trials Blog Clinical Trials Drug Pricing
Datamonitor Healthcare: data analysis and insight
The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit.
Datamonitor Healthcare: data analysis and insight, Biomedtra...
Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: